Matthew Autterson Is Helping Change the World for Disabled Individuals
Posted on : 02-26-2018 By : Samantha Pointer
Matthew Autterson is a distinguished graduate of Michigan State University. He received a BA degree in Finance in 1980. He also attended the graduate tax program offered at the University of Denver. He started his career at First Trust Corporation, but left in 1982. He then joined a team that chartered a trust company in Colorado State. Autterson took on the role of President for Resources Trust Company. As such, Autterson has a great deal of financial and business experience that allows him to successfully lead the organization.   Matthew…
Read More
0 Comments
Matthew Autterson: Handling a Constantly Changing Firm
Posted on : 01-29-2018 By : Samantha Pointer
Matthew Autterson is a hardworking and dedicated man who wanted to excel in the world of finance. He has been working in the industry for more than 25 years, and he acquired skills that are essential for his career advancement. By working in the financial sector, Matthew Autterson learned about the secrets in having a financially stable life, and he is sharing the knowledge that he acquired from his job. Today, he continues to work hard and show the world that he deserves being an executive because of the skills…
Read More
0 Comments
Matthew Autterson and his Contributions to Finance and the Community
Posted on : 01-25-2018 By : Samantha Pointer
Matthew Autterson is working in business and philanthropy. He achieved his higher education from the Michigan State University, graduating in 1980 with a bachelor's degree in Finance. He continued expanding his training in the field at the Tax Program hosted by the University of Denver before moving on into his business career.     The First Trust Corporation was the first place that Matthew Autterson worked at until 1982. After that, he joined a team of charter professionals and took part in the establishment of the subsidiary Resource Trust Company,…
Read More
0 Comments
The grand plan by Seattle Genetics to produce 12 more drugs and get 100 more employees
Posted on : 10-19-2016 By : Samantha Pointer
The cancer research center, settle genetics, which trades as SGEN on NASDAQ is set to try out 12 new drugs and also to go on a hiring spree for 100 new employees. The goal that the company has in mind is widening the use of their current drug and also creating new drugs. This comes after a visit by the vice president Joe Bidden to the facility. These developments are evidence of the level of drive that the company is operating under and also the role of the city as…
Read More
0 Comments
The Innovative Vision of Clay Siegall and Seattle Genetics
Posted on : 07-13-2016 By : Samantha Pointer
  Seattle Genetics is a company working on revolutionizing cancer therapy. At the head of that revolution is co-founder and CEO Dr. Clay Siegall. For the past 17 years, Seattle Genetics, under Dr. Siegall’s leadership, has worked to create breakthrough concepts in cancer therapies through the research and development of antibody-drug conjugates, or ADC’s. ADC’s are a targeted therapy in the treatment of cancer, inhibiting the growth of cancerous cells without damaging the body’s healthy cells like traditional chemotherapy. Seattle Genetics dedication and tireless research continue to innovate and show encouraging progress in antibody-drug conjugates. Through Dr. Siegall’s guidance and direction, Seattle Genetics technological advances have contributed to the development of more than 20 ADC’s. Siegall, a graduate of the University of Maryland, and George Washington University is committed to the company’s growth and continued research. Thanks to his vigorous efforts, he has managed to secure more than 675 million dollars through private and public funding. International partnerships have also contributed to the company’s growth and assets. Dr. Siegall is proud of the research and technologies Seattle Genetics has created in its crusade against cancer. The company’s ADCETRIS, a new class of ADC’s, has shown positive results in more than 15,000 lymphoma patients in the U.S and abroad. About half of the patients that undergo autologous stem cell transplant face the threat of relapsing. Seattle Genetics is working to develop new therapies that would reduce the risk and increase the patient’s chances of a successful recovery. With their dedication, continued research, and fundraising, Dr. Siegall, and Seattle Genetics will continue to lead the way in cancer treatment innovation. Read about Clay: http://www.seattlegenetics.com/clay_siegall
Read More
0 Comments